What is Combinostics?
Combinostics specializes in the development of advanced artificial intelligence technology designed to streamline the diagnosis and longitudinal management of neurological disorders. Its flagship solution, cNeuro, serves as a comprehensive clinical decision support platform that synthesizes cMRI and cDSI applications. By providing radiologists and neurologists with a unified view of patient data, the company facilitates more precise diagnostic workflows. The platform is engineered to enhance collaboration across multidisciplinary medical teams, leveraging cloud-based architecture to ensure that actionable insights are accessible, thereby improving the standard of care for patients suffering from complex brain-related pathologies.
How much funding has Combinostics raised?
Combinostics has raised a total of $4.3M across 1 funding round:
Series A
$4.3M
Series A (2019): $4.3M with participation from NordicNinja VC and Industrifonden
Key Investors in Combinostics
Industrifonden
A Swedish venture capital fund that invests in unique, scalable innovations aimed at improving society through breakthrough technologies and science, with a specific focus on life sciences and deep tech.
NordicNinja VC
A venture capital firm focused on supporting deep-tech and digital transformation startups across the Nordic and Baltic regions, providing strategic guidance for international scaling.
What's next for Combinostics?
With the successful closure of this major enterprise-level funding, Combinostics is poised to accelerate its market penetration and expand the functional capabilities of the cNeuro platform. The strategic roadmap likely involves deepening the integration of its AI algorithms with existing hospital information systems to drive broader adoption among clinical practitioners. Furthermore, the capital will support the scaling of operations to meet the increasing demand for data-driven neurological diagnostics. As the company matures, the focus will shift toward long-term clinical validation and the expansion of its footprint in international healthcare markets, ensuring that its technology remains at the forefront of the neuro-diagnostic revolution.
See full Combinostics company page
